Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anastasia Paz"'
Autor:
Erez Lavi, Neta Zilony Hanin, Zohar Pode, Anastasia Paz, Neria Reiss, Vitaliy Buravenkov, Itay Liron, Raanan Berger, Ido Bachelet, Guy Neev, Irit Carmi Levy, Karin Mizrahi, Ronit Farhi, Chen Shimoni, Liron Levy-Efrati, Rotem Haimovich, Ohad Glaich, Hadas Aharoni Zazrin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/2c168dc6f6a44513ab7b491f993eeb46
Autor:
Erez Lavi, Nir Skalka, Neta Zilony Hanin, Zohar Pode, Anastasia Paz, Yeela Scharff, Neria Reiss, Omer Levy, Elinor Debby, Liron Levy- Efrati, Vitaliy Buravenkov, Itay Liron, Yaniv Amir, Raanan Berger, Ido Bachelet, Guy Neev, Irit Carmi Levy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/e5c71e7377e341459d981133f37bd636
Autor:
Neria Reiss, Avichai Shimoni, Adva Zamir, Gil Harari, Gil Loewenthal, Elinor Debby, Anastasia Paz, Yaniv Amir, Erez Lavi, Almogit Abu-Horowitz, Irit Avivi, Liron Bassali, Nir Skalka, Itai Rusinek, Noam Mamet, Guy Neev, Ido Bachelet, Mor Greenberg
Publikováno v:
Communications Biology, Vol 3, Iss 1, Pp 1-9 (2020)
Communications Biology
Communications Biology
Drug discovery is challenged by ineffectiveness of drugs against variable and evolving diseases, and adverse effects due to poor selectivity. We describe a robust platform which potentially addresses these limitations. The platform enables rapid disc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4cc86ba8d7b3c4e8b677e10f0d9aa4
https://doi.org/10.1038/s42003-020-0756-0
https://doi.org/10.1038/s42003-020-0756-0
Autor:
Hadas Aharoni Zazrin, Chen Shimoni, Itay Liron, Neria Reiss, Irit Carmi Levy, Anastasia Paz, Karin Mizrahi, Guy Neev, Ido Bachelet, Liron Levy-Efrati, Raanan Berger, Ronit Farhi, Erez Lavi, Neta Zilony Hanin, Rotem Haimovich, Ohad Glaich, Zohar Pode, Vitaliy Buravenkov
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundT-cell engagers are bispecific molecules directed against the CD3 complex on one end and a tumor specific antigen on the other end, allowing a physical link of T cell to a tumor cell, resulting in tumor killing and immune activation. Bispec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63679e273c47fef7d6a9f7e7ccdb64e6
https://doi.org/10.1136/jitc-2021-sitc2021.788
https://doi.org/10.1136/jitc-2021-sitc2021.788
Autor:
Noam Mamet, Avichai Shimoni, Elinor Debby, Almogit Abu-Horowitz, Mor Greenberg, Ido Bachelet, Anastasia Paz, Itai Rusinek, Gil Harari, Yaniv Amir, Nir Skalka, Gil Loewenthal, Guy Neev, Neria Reiss, Adva Zamir, Liron Bassali, Irit Avivi, Erez Lavi
Our current model of drug discovery is challenged by the relative ineffectiveness of drugs against highly variable and rapidly evolving diseases and their relatively high incidence of adverse effects due to poor selectivity. Here we describe a robust
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5d0ae9a77d9b5b1e339fa1a02977a3
https://doi.org/10.1101/629105
https://doi.org/10.1101/629105
Autor:
Anastasia Pazaiti, Ian S. Fentiman
Publikováno v:
International Journal of Breast Cancer, Vol 2011 (2011)
Sentinel lymph node biopsy (SLNB) is a safe and accurate minimally invasive method for detecting axillary lymph node (ALN) involvement in the clinically negative axilla thereby reducing morbidity in patients who avoid unnecessary axillary lymph node
Externí odkaz:
https://doaj.org/article/f0fc252bc9ac421a93204e6ed3073636